Vittoria Biotherapeutics Announces FDA Clearance of IND Application for VIPER-101 to Treat T-Cell Lymphoma
VIPER-101 is an autologous, CD5 knock-out CAR-T therapy for the treatment of T-cell lymphoma
Initiating first-in-human Phase 1 trial in H1 of 2024
Palvella Therapeutics and Ligand Pharmaceuticals Expand Strategic Partnership to Accelerate Phase 3 Development of QTORIN™ rapamycin for Microcystic Lymphatic Malformations and Additional High Unmet Need Clinical Indications
Palvella Received $5 Million Upfront Payment
QTORIN™ rapamycin has Potential to be First FDA Approved Therapy and Standard of Care in the U.S. for an Estimated more than 30,000 Diagnosed Patients with Microcystic Lymphatic Malformations
U.S. FDA Breakthrough Therapy Designation Granted to QTORIN™ rapamycin for the Treatment of Microcystic Lymphatic Malformations in November 2023
Opsidio Announces First Patient Dosed in Phase 2a Trial of OpSCF in Moderate to Severe Atopic Dermatitis
– OpSCF is a novel monoclonal antibody directed against the inflammatory form of stem cell factor
Palvella Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations
QTORIN™ rapamycin has potential to be first approved therapy and standard of care in the U.S. for Microcystic Lymphatic Malformations
Microcystic Lymphatic Malformations is a chronically debilitating and lifelong genetic disease affecting an estimated more than 30,000 patients in the U.S.
SIRPant Immunotherapeutics Receives FDA Orphan Drug Designation for SIRPant-M for the Treatment of T-Cell Lymphoma
Vittoria Biotherapeutics Secures Over $15 Million in Private Financing Round to Support the Development of Novel CAR-T Cell Therapies
Funds to support advancement of lead candidate, VIPER-101, to the clinic
ONCO, Inc. Announces Strategic Partnership with Oncora Medical to Launch Data-Driven Software Automation to Enhance Patient Care and Oncology Data Management.
Melinta Therapeutics and Venatorx Pharmaceuticals Announce Licensing Agreement to Commercialize Cefepime-Taniborbactam in the U.S.
Immunome Reports Third Quarter 2023 Financial Results
– Completed merger with Morphimmune and concurrent $125 million private placement investment with leading institutional investors
– Clay B. Siegall, Ph.D., former co-founder & CEO of Seagen, Inc., appointed as Chairman and CEO
– Bob Lechleider, M.D., appointed as Chief Medical Officer
– Jean-Jacques Bienaimé, former CEO of BioMarin appointed as member of the Board of Directors
– Cash runway expected to extend into Q1 2026*